PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients

Event: ESC CONGRESS 2015
Topic: Lipids
Session type: Satellite Symposium - Experts on the Spot
Sponsored by Amgen
Date: 1 September 2015
Time: 15:45 - 16:15

1 presentations in this session

PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients.

Thumbnail

This platform is supported by

logo Novo Nordisk